Boenning & Scattergood’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
$2.76M Sell
9,624
-916
-9% -$325K 0.44% 55
2022
Q3
$3.41M Buy
10,540
+916
+10% +$290K 0.7% 36
2022
Q2
$3.12M Hold
9,624
0.59% 42
2022
Q1
$2.76M Buy
9,624
+27
+0.3% +$6.95K 0.44% 55
2021
Q4
$2.65M Buy
9,597
+225
+2% +$57K 0.42% 58
2021
Q3
$2.17M Sell
9,372
-75
-0.8% -$18.5K 0.38% 67
2021
Q2
$2.17M Buy
9,447
+125
+1% +$25.1K 0.38% 71
2021
Q1
$1.74M Buy
9,322
+600
+7% +$117K 0.33% 81
2020
Q4
$1.47M Buy
8,722
+7
+0.1% +$1.04K 0.31% 90
2020
Q3
$1.29M Buy
8,715
+254
+3% +$39.3K 0.31% 81
2020
Q2
$1.39M Buy
8,461
+3,105
+58% +$477K 0.37% 67
2020
Q1
$743K Sell
5,356
-15
-0.3% -$2.06K 0.26% 101
2019
Q4
$706K Hold
5,371
0.18% 136
2019
Q3
$601K Sell
5,371
-75
-1% -$8.35K 0.17% 146
2019
Q2
$603K Buy
5,446
+425
+8% +$50K 0.18% 145
2019
Q1
$652K Sell
5,021
-2,400
-32% -$292K 0.2% 133
2018
Q4
$859K Sell
7,421
-2,840
-28% -$317K 0.3% 97
2018
Q3
$1.1M Buy
10,261
+400
+4% +$40K 0.35% 78
2018
Q2
$841K Buy
+9,861
New +$810K 0.28% 107

Other funds holding LLY

Boenning & Scattergood's LLY Position: Q4 2022 in Review

Boenning & Scattergood reduced its Eli Lilly (LLY) stake by 8.7% in Q4 2022, selling an estimated $325K and leaving 9,624 shares worth $2.76M. The position accounts for 0.44% of the portfolio, ranked #55.

Boenning & Scattergood first reported a position in LLY in Q2 2018 and has held it in 19 quarters since. The position peaked at $3.41M in Q3 2022. 2,671 funds tracked by Wall St. Rank hold LLY as of Q4 2022.

  • Boenning & Scattergood held 9,624 shares of Eli Lilly worth $2.76M as of Q4 2022.
  • Boenning & Scattergood sold 916 Eli Lilly shares in Q4 2022, an estimated $325K.
  • Eli Lilly made up 0.44% of Boenning & Scattergood's portfolio in Q4 2022, its #55 holding.
  • Boenning & Scattergood first reported a position in Eli Lilly in Q2 2018 and has held it in 19 quarters since.
  • Boenning & Scattergood's Eli Lilly position peaked at $3.41M in Q3 2022.
  • 2,671 funds tracked by Wall St. Rank held Eli Lilly as of Q4 2022.

Based on Boenning & Scattergood's 13F filing for Q4 2022, filed 26 Jan 2023.